PREGNANCY TERMINATION AT PRENATALLY DIAGNOSTIFIED FETAL ANOMALY: TWO PROTOCOL COMPARATION

M. Bogovac ,
M. Bogovac

Clinical Centre, Department of Obstetrics and Gynecology , Novi Sad , Serbia

D. Bettelheim ,
D. Bettelheim

Universitasklinik fur frauenheilkunde, Allgemaines krankenhaus, Klin Abteilung fur Gynakol und Geburtshilfe

G. Relić
G. Relić

Department of obstertrics and Gynecology, Medical School of Prishtina , Kosovska Mitrovica , Kosovo*

Published: 01.12.2006.

Volume 34, Issue 2 (2006)

pp. 21-24;

https://doi.org/10.70949/pramed200602149B

Abstract

Medical abortion (i.e. abortion induced by pharmaceutical agents) is a method of pregnancy termination administered most often in the second trimester in case of either fetal malformations or absence of fetal heart tones (missed abortion. Aim of the study was to compare effects of two regimens of drug adminstration for pregnancy termination in case of fetal anomalies registered in the second trimester of pregnancy. The investigation was performed in 52 patients of the Universitasklinik fur frauenheilkunde, Allgemaines krankenhaus (AKH), Klinische Abteilung fur Gynakologie und Geburtshilfe, Abteilung fur pranatale diagnostic und therapie and comprised two groups of patients in whom pregnancy termination was performed in the second trimester because of the presence of fetal malformations. Comparison analysis of the effect of the two regimens for pregnancy termination has been conducted in two groups of patients: Group A, who received R R R Cergem (Gemeprost) and Group B, who received a combination of Myfegine (Myfepriston) and Cyprostol (Misoprostol). Complete medical abortion occurred approximately at the same rate in both investigated groups (Group A - 10 (35.7%); Group B - 9 (37.5%). Curettage (Vacum aspiration) following the incomplete medical abortion was required in the group R R with Gemeprost in 18 (64.3%), and in the group with Myfegine /Cyprostol in 15 (62.5%) patients. A regimen of mifepristone pre-treatment followed by misoprostol applied in the Group B presented with financial benefits according to the present time prices of drugs in Austria relative to the regimen administered in the Group A, in which the cost of a single or a two-day treatment by gemeprost was significantly more expensive.

Keywords

References

1.
P. LR, G. P, L. H, R. N, H. ER, C R. Second trimester termination of pregnancy for fetal anomaly or death: comparing mifepristone/misoprostol to gemeprost. European Journal of Obstetrics & Gynecology and Reproductive Biology. 95(ue 1):52–4.
2.
O.S. T, K.J T. Second trimester medical abortion with mifepristone and gemeprost: a review of 956 cases. Contraception. 64(ue 1):29–32.
3.
M. C, J. S, H. P, W F. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. British Journal of Obstetrics and Gynaecology. 108(ue 5):469–73.
4.
P. A, H. H, F. N, G. F, A T. Randomised controlled study comparing oral and vaginal misoprostol for cervical priming prior to surgical termination of pregnancy. BJOG: An International Journal of Obstetrics and Gynaecology. 110(ue 12):1057–61.
5.
J. D, F S. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstetrics & Gynecology. 101(ue 6):1294–9.
6.
M. B, K. GD, L. M, M.L S. Pregnancy termination. Steroids. 65(ues 10-11):801–5.
7.
Sarkar N. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. European Journal of Obstetrics & Gynecology and Reproductive Biology. 101(ue 2):113–20.
8.
I. M, M. S, P. S, E. Z, B T. Misoprostol in second and early third trimester for termination of pregnancies with fetal anomalies. International Journal of Gynecology & Obstetrics. 79(ue 2):131–5.
9.
J. B, D B. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG: An International Journal of Obstetrics and Gynaecology. 109(ue 11):1290–4.
10.
Heus R., G. G, G. C, H. B, B M. Medical management for termination of second and third trimester pregnancies: a comparison of strategies. European Journal of Obstetrics & Gynecology and Reproductive Biology. 116(ue 1, September 10):16–21.
11.
S. P, T T. Misoprostol for second trimester termination of pregnancies with prior low transverse cesarean section. International Journal of Gynecology & Obstetrics. 80(ue 1):61–2.
12.
A. C, Y. H, P P. Randomized trial of oral and vaginal misoprostol to manage delivery in cases of fetal death. Obstetrics & Gynecology. 101(ue 1):70–3.
13.
J. D, S E. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. American Journal of Obstetrics and Gynecology. 186(ue 3):470–4.
14.
S. P, T T. Intravaginal misoprostol for pregnancy termination. International Journal of Gynecology & Obstetrics. 87(ue 2):176–7.
15.
J. J, R A. Termination of pregnancy. Current Obs & Gyn. 14(ue 4):285–90.
16.
E. W, S. D, E. G, F. J, L L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstetrics & Gynecology. 99(ue 5, Part 1):813–9.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by